IP3 3-kinase B controls hematopoietic stem cell homeostasis and prevents lethal hematopoietic failure in mice

S Siegemund, S Rigaud, C Conche… - Blood, The Journal …, 2015 - ashpublications.org
S Siegemund, S Rigaud, C Conche, B Broaten, L Schaffer, L Westernberg, SR Head…
Blood, The Journal of the American Society of Hematology, 2015ashpublications.org
Tight regulation of hematopoietic stem cell (HSC) homeostasis ensures lifelong
hematopoiesis and prevents blood cancers. The mechanisms balancing HSC quiescence
with expansion and differentiation into hematopoietic progenitors are incompletely
understood. Here, we identify Inositol-trisphosphate 3-kinase B (Itpkb) as an essential
regulator of HSC homeostasis. Young Itpkb−/− mice accumulated phenotypic HSC, which
were less quiescent and proliferated more than wild-type (WT) controls. Itpkb−/− HSC …
Abstract
Tight regulation of hematopoietic stem cell (HSC) homeostasis ensures lifelong hematopoiesis and prevents blood cancers. The mechanisms balancing HSC quiescence with expansion and differentiation into hematopoietic progenitors are incompletely understood. Here, we identify Inositol-trisphosphate 3-kinase B (Itpkb) as an essential regulator of HSC homeostasis. Young Itpkb−/− mice accumulated phenotypic HSC, which were less quiescent and proliferated more than wild-type (WT) controls. Itpkb−/− HSC downregulated quiescence and stemness associated, but upregulated activation, oxidative metabolism, protein synthesis, and lineage associated messenger RNAs. Although they had normal-to-elevated viability and no significant homing defects, Itpkb−/− HSC had a severely reduced competitive long-term repopulating potential. Aging Itpkb−/− mice lost hematopoietic stem and progenitor cells and died with severe anemia. WT HSC normally repopulated Itpkb−/− hosts, indicating an HSC-intrinsic Itpkb requirement. Itpkb−/− HSC showed reduced colony-forming activity and increased stem-cell-factor activation of the phosphoinositide-3-kinase (PI3K) effectors Akt/mammalian/mechanistic target of rapamycin (mTOR). This was reversed by treatment with the Itpkb product and PI3K/Akt antagonist IP4. Transcriptome changes and biochemistry support mTOR hyperactivity in Itpkb−/− HSC. Treatment with the mTOR-inhibitor rapamycin reversed the excessive mTOR signaling and hyperproliferation of Itpkb−/− HSC without rescuing colony forming activity. Thus, we propose that Itpkb ensures HSC quiescence and function through limiting cytokine-induced PI3K/mTOR signaling and other mechanisms.
ashpublications.org